Key Takeaways
- • Six registered funds holding $707M in IQHQ positions marked down valuations in H2 2025, signaling distress in the lab real estate sector following a wave of megadevelopments launched in 2022–2023.
- • IQHQ, one of the largest privately held lab developers with a 3.6M SF operational portfolio, secured $900M in rescue financing in January 2025 from a consortium including Morgan Stanley and CenterSquare Investment Management, yet continues facing creditor pressure.
- • Bluerock, IQHQ's largest shareholder with over $700M exposure, marked down its Bluerock Total Income+ Real Estate Fund by 4.4% to $6.28 per share in H2 2025; the fund has lost approximately 40% of its value since its NYSE listing in December 2025 and has posted nine consecutive quarters of negative returns.
- • Valuation divergence among IQHQ investors is stark: T. Rowe Price marked common equity at $4.92 per unit, while an Altegris fund valued it at $2.26—reflecting widespread uncertainty about the company's recovery prospects.
- • IQHQ leadership disputes distress characterization despite mounting financial pressures, while the company maintains a significant development pipeline including a $1.9B Research and Development District in downtown San Diego.
Summary
IQHQ, one of the country's largest privately held life sciences real estate developers, faces mounting financial headwinds as six registered funds holding $707M in allocated capital marked down positions in the second half of 2025. The markdowns underscore broader distress in the lab leasing market, which experienced a construction surge in 2022 and 2023 that has since failed to materialize into strong occupancy and rental growth.
With an operational portfolio spanning 3.6M square feet, IQHQ counts prominent institutional investors among its stakeholders, including Bluerock, T. Rowe Price, Morgan Stanley, and CenterSquare Investment Management. The company secured $900M in rescue financing in January 2025 from a consortium that reportedly included Morgan Stanley and CenterSquare, yet these funds have not halted the valuation erosion across its investor base.
Bluerock Residential Growth REIT (BRG), IQHQ's largest shareholder with exposure exceeding $700M, marked down its Bluerock Total Income+ Real Estate Fund by 4.4% to $6.28 per share in H2 2025. The fund has suffered acute losses since its December 2025 NYSE listing, declining approximately 40% on its first trading day and posting nine consecutive quarters of negative returns, leaving investors in an extended redemption queue. Other IQHQ investors have recorded steeper markdowns: Highland Opportunities and Income Fund and NexPoint Real Estate Strategies Fund each reduced valuations by 23% to $7.72, while T. Rowe Price positioned common equity at $4.92 per unit and an Altegris fund valued positions at $2.26—reflecting significant divergence in investor confidence and valuation methodology.
Despite the mounting evidence of financial strain, an unnamed member of IQHQ leadership disputed characterizations of company distress, citing disclosure sensitivities. The company maintains an ambitious development agenda, including a $1.9B Research and Development District in downtown San Diego. However, the combination of creditor pressures, nine-figure markdowns by major funds, and a challenging lab leasing environment suggest that IQHQ's operational recovery and valuation stabilization remain uncertain near-term prospects for its institutional backers.
With an operational portfolio spanning 3.6M square feet, IQHQ counts prominent institutional investors among its stakeholders, including Bluerock, T. Rowe Price, Morgan Stanley, and CenterSquare Investment Management. The company secured $900M in rescue financing in January 2025 from a consortium that reportedly included Morgan Stanley and CenterSquare, yet these funds have not halted the valuation erosion across its investor base.
Bluerock Residential Growth REIT (BRG), IQHQ's largest shareholder with exposure exceeding $700M, marked down its Bluerock Total Income+ Real Estate Fund by 4.4% to $6.28 per share in H2 2025. The fund has suffered acute losses since its December 2025 NYSE listing, declining approximately 40% on its first trading day and posting nine consecutive quarters of negative returns, leaving investors in an extended redemption queue. Other IQHQ investors have recorded steeper markdowns: Highland Opportunities and Income Fund and NexPoint Real Estate Strategies Fund each reduced valuations by 23% to $7.72, while T. Rowe Price positioned common equity at $4.92 per unit and an Altegris fund valued positions at $2.26—reflecting significant divergence in investor confidence and valuation methodology.
Despite the mounting evidence of financial strain, an unnamed member of IQHQ leadership disputed characterizations of company distress, citing disclosure sensitivities. The company maintains an ambitious development agenda, including a $1.9B Research and Development District in downtown San Diego. However, the combination of creditor pressures, nine-figure markdowns by major funds, and a challenging lab leasing environment suggest that IQHQ's operational recovery and valuation stabilization remain uncertain near-term prospects for its institutional backers.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.